Search Within

Larry Norton

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (38)
  2. Journal Article (26)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (64)
  2. Breast Medicine Service (64)
  3. Department of Medicine (64)
  4. GSK Faculty (64)
  5. Human Oncology and Pathogenesis Program (64)
  6. Solid Tumor Oncology Division (64)

More Groups

People
  1. Sarat Chandarlapaty (36)
  2. Jorge Reis-Filho (25)
  3. David Solit (23)
  4. Shanu Modi (21)
  5. Michael Berger (20)
  6. Clifford Hudis (18)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (15)
  2. Cancer Research (10)
  3. Clinical Cancer Research (6)
  4. Laboratory Investigation (4)
  5. npj Breast Cancer (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. American Society of Clinical Oncology (17)
  3. Nature Publishing Group (12)
  4. Oxford University Press (6)
  5. Nature Research (4)
  6. American Society of Hematology (2)

More Publishers

Results (64)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer
    Meeting Abstract

    Gajria, D.; King, T. A.; Pannu, H.; Sakr, R.; Seidman, A. D.; Syldor, A.; Patil, S.; Maybody, M.; Norton, L.; Rosen, N.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
    Journal Article

    Chandarlapaty, S.; Scaltriti, M.; Angelini, P.; Ye, Q.; Guzman, M.; Hudis, C. A.; Norton, L.; Solit, D. B.; Arribas, J.; Baselga, J.; more...
    Oncogene (2010)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers
    Journal Article

    Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save